IL2 and neoplasm: OBP-301, an OAd with hTERT-driven E1A/E1B, showed strong anti-tumor activity in orthotopic and metastatic RCC mouse models, the anti-tumor effects were further enhanced by IL-2 co-administration (Huang et al., 2010).